With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Feature|Articles|July 7, 2026
- Vol.27/No.9
- Volume 27
- Issue 09
AI Finds New Applications in Oncologic Surgery, Drug and Biomarker Screening, and Clinical Trial Design
Author(s)Kyle Doherty
Fact checked by: Courtney Flaherty, Tracy Ann Politowicz
OncLive spoke with expert investigators to gather insights on the role of AI in cancer care, including oncologic surgery and drug development.
Advertisement
Advertisement
Artificial intelligence (AI) is rapidly moving beyond the realm of future promise and into everyday oncology practice. From enhancing surgical precision and diagnostic accuracy to refining biomarker-driven treatment selection and streamlining clinical trial enrollment, AI-powered tools are beginning to fundamentally reshape how cancer care is delivered.
Related to this article
Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Advertisement
Advertisement